Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers-Reference-Cited by-同舟云学术

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Published:2008-11-30 Issue:12 Volume:14 Page:1351-1356
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Engelman Jeffrey A,Chen Liang,Tan Xiaohong,Crosby Katherine,Guimaraes Alexander R,Upadhyay Rabi,Maira Michel,McNamara Kate,Perera Samanthi A,Song Youngchul,Chirieac Lucian R,Kaur Ramneet,Lightbown Angela,Simendinger Jessica,Li Timothy,Padera Robert F,García-Echeverría Carlos,Weissleder Ralph,Mahmood Umar,Cantley Lewis C,Wong Kwok-Kin

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.1890.pdf

Reference21 articles.

1. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).

2. Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485–495 (2006).

3. Li, D. et al. Bronchial and peripheral murine lung carcinomas induced by T790M–L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12, 81–93 (2007).

4. Fisher, G.H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249–3262 (2001).

5. Perl, A.K., Tichelaar, J.W. & Whitsett, J.A. Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res. 11, 21–29 (2002).

Cited by 1171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

2. Tumor antigen presentation and the associated signal transduction during carcinogenesis;Pathology - Research and Practice;2024-09

3. Functional and structural insights into RAS effector proteins;Molecular Cell;2024-08

4. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01

5. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?;Lung Cancer;2024-08